|
4 Companies |
|
3 Products |
|
3 Products |
|
7 Mechanisms of Action |
|
0 Trials |
|
46 News |
|
- | Enrollment change, Trial completion date, Trial withdrawal: The Metabolomics of Anaphylaxis to Immunotherapy (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
N=12 --> 0 | Trial completion date: Dec 2018 --> Aug 2018 | Active, not recruiting --> Withdrawn
- | Enrollment change, Trial completion date, Trial withdrawal: The Metabolomics of Anaphylaxis (clinicaltrials.gov) - Mar 7, 2019
P=N/A, N=0, Withdrawn, Sponsor: Massachusetts General Hospital
N=12 --> 0 | Trial completion date: Dec 2018 --> Aug 2018 | Active, not recruiting --> Withdrawn N=12 --> 0 | Trial completion date: Dec 2018 --> Aug 2018 | Active, not recruiting --> Withdrawn
- | Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion, Trial completion date, Trial primary completion date: Inhibition of Anaphylaxis by Ibrutinib (clinicaltrials.gov) - Nov 16, 2018
P2, N=6, Completed, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
N=12 --> 0 | Trial completion date: Dec 2018 --> Aug 2018 | Active, not recruiting --> Withdrawn Recruiting --> Completed | Trial completion date: Sep 2017 --> Nov 2018 | Trial primary completion date: Sep 2017 --> Nov 2018
- | Trial completion: SMARTER: Smartphone Apps for Pediatric Resuscitation (clinicaltrials.gov) - Oct 6, 2017
P=N/A, N=40, Completed, Sponsor: St. Justine's Hospital
Recruiting --> Completed | Trial completion date: Sep 2017 --> Nov 2018 | Trial primary completion date: Sep 2017 --> Nov 2018 Recruiting --> Completed
- ||| Trial completion, Trial primary completion date: Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device (clinicaltrials.gov) - Jul 25, 2017
P=N/A, N=100, Completed, Sponsor: Adan Medical Innovation, SL
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2017
- | Imbruvica (ibrutinib) / AbbVie, J&J
New P2 trial: Inhibition of Anaphylaxis by Ibrutinib (clinicaltrials.gov) - May 10, 2017
P2, N=6, Recruiting, Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
- | Enrollment open: SMARTER: Smartphone Apps for Pediatric Resuscitation (clinicaltrials.gov) - Apr 19, 2017
P=N/A, N=40, Recruiting, Sponsor: St. Justine's Hospital
Active, not recruiting --> Completed | Trial primary completion date: Apr 2017 --> Jul 2017 Not yet recruiting --> Recruiting
- | Trial completion, Surgery: Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=30, Completed, Sponsor: Mustafa Kemal University
Not yet recruiting --> Recruiting Recruiting --> Completed
- || Enrollment closed: Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device (clinicaltrials.gov) - Jan 10, 2017
P=N/A, N=100, Active, not recruiting, Sponsor: Adan Medical Innovation, SL
Recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion, Trial primary completion date: Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children (clinicaltrials.gov) - Jan 4, 2017
P4, N=28, Completed, Sponsor: Tampere University Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016
- New trial: SMARTER: Smartphone Apps for Pediatric Resuscitation (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: St. Justine's Hospital
- Trial completion, Enrollment change: Molecular Mechanisms and Diagnosis of Mastocytosis (clinicaltrials.gov) - Nov 7, 2016
P=N/A, N=136, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Completed | N=200 --> 136
- Enrollment closed, Trial primary completion date: The Metabolomics of Anaphylaxis (clinicaltrials.gov) - Oct 13, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=200 --> 136 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2017
- Enrollment closed, Trial primary completion date: The Metabolomics of Anaphylaxis to Immunotherapy (clinicaltrials.gov) - Oct 12, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2017
- New trial: Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device (clinicaltrials.gov) - Aug 4, 2016
P=N/A, N=100, Recruiting, Sponsor: Adan Medical Innovation, SL
- Enrollment open, Surgery: Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions (clinicaltrials.gov) - Feb 5, 2016
P=N/A, N=30, Recruiting, Sponsor: Mustafa Kemal University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2017 Not yet recruiting --> Recruiting
- Trial completion: NASA: Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=200, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Recruiting --> Completed
- New trial, Surgery: Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions (clinicaltrials.gov) - Jan 4, 2016
P=N/A, N=30, Not yet recruiting, Sponsor: Mustafa Kemal University
- New trial: One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=200, Completed, Sponsor: Stefania La Grutta, MD
- heparin sodium injection / Generic mfg.
Enrollment change: Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department (clinicaltrials.gov) - May 12, 2015
P=N/A, N=0, Withdrawn, Sponsor: Truman Medical Center
Recruiting --> Completed N=60 --> 0
- Trial primary completion date: NASA: Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents (clinicaltrials.gov) - Apr 25, 2015
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - H
N=60 --> 0 Trial primary completion date: Jul 2014 --> Jul 2015
- Trial completion: Promoting Tolerance to Peanut in High-Risk Children (clinicaltrials.gov) - Feb 26, 2015
P2, N=640, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jul 2014 --> Jul 2015 Active, not recruiting --> Completed
- Biomarker, Trial completion: STOP: Study of Tolerance to Oral Peanut (clinicaltrials.gov) - Jan 15, 2015
P1, N=22, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment status, Trial primary completion date: The Metabolomics of Anaphylaxis to Immunotherapy (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=12, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2013 --> Jun 2016
- Enrollment status, Trial primary completion date: The Metabolomics of Anaphylaxis (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=12, Recruiting, Sponsor: Massachusetts General Hospital
Enrolling by invitation --> Recruiting | Trial primary completion date: Jun 2013 --> Jun 2016 Enrolling by invitation --> Recruiting | Trial primary completion date: Dec 2012 --> Jul 2016
- ||| Bridion (sugammadex) / Merck (MSD)
Trial completion: A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) (clinicaltrials.gov) - Jul 16, 2014
P1, N=383, Completed, Sponsor: Merck Sharp & Dohme Corp.
Enrolling by invitation --> Recruiting | Trial primary completion date: Dec 2012 --> Jul 2016 Active, not recruiting --> Completed
- Trial completion: Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis (clinicaltrials.gov) - Apr 9, 2014
P=N/A, N=10, Completed, Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Xolair (omalizumab) / Roche, Novartis
Enrollment change: X-PAND: Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing (clinicaltrials.gov) - Mar 6, 2014
P4, N=118, Completed, Sponsor: Genentech
Active, not recruiting --> Completed N=150 --> 118
- |||| Xolair (omalizumab) / Roche, Novartis
Trial completion: X-PAND: Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing (clinicaltrials.gov) - Mar 6, 2014
P4, N=118, Completed, Sponsor: Genentech
N=150 --> 118 Recruiting --> Completed
- || Bridion (sugammadex) / Merck (MSD)
Enrollment closed: A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) (clinicaltrials.gov) - Mar 4, 2014
P1, N=375, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Bridion (sugammadex) / Merck (MSD)
New P1 trial: A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101) (clinicaltrials.gov) - Jan 2, 2014
P1, N=375, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- Enrollment change: Potential Allergens in Wine: Double-blind Placebo-controlled Trial (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=48, Completed, Sponsor: Bayside Health
Recruiting --> Active, not recruiting N=40 --> 48
- Trial completion: Potential Allergens in Wine: Double-blind Placebo-controlled Trial (clinicaltrials.gov) - Dec 2, 2013
P=N/A, N=48, Completed, Sponsor: Bayside Health
N=40 --> 48 Recruiting --> Completed
- Enrollment change: Safe Administration of Flu Vaccine to Egg Allergic Children (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=31, Completed, Sponsor: University of Michigan
Recruiting --> Completed N=200 --> 31
- Trial completion: Safe Administration of Flu Vaccine to Egg Allergic Children (clinicaltrials.gov) - Jun 5, 2013
P=N/A, N=31, Completed, Sponsor: University of Michigan
N=200 --> 31 Recruiting --> Completed
- Enrollment open: NASA: Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents (clinicaltrials.gov) - Mar 3, 2013
P=N/A, N=200, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed Not yet recruiting --> Recruiting